Evidence map›Paper›PMID 32470038›Full record

ArticlePloS one2020

Differential effects of Fe2+ and Fe3+ on osteoblasts and the effects of 1,25(OH)2D3, deferiprone and extracellular calcium on osteoblast viability under iron-overloaded conditions.

Kornkamon Lertsuwan, Ketsaraporn Nammultriputtar, Supanan Nanthawuttiphan, Natnicha Tannop, Jarinthorn Teerapornpuntakit, Jirawan Thongbunchoo, Narattaphol Charoenphandhu

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Extracellular FeScientific reports · 2023
    Article
  5. Review
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Kornkamon LertsuwanDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.
Ketsaraporn NammultriputtarCenter of Calcium and Bone Research (COCAB), Faculty of Science, Mahidol University, Bangkok, Thailand.
Supanan NanthawuttiphanDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.
Natnicha TannopDepartment of Biochemistry, Faculty of Science, Mahidol University, Bangkok, Thailand.
Jarinthorn TeerapornpuntakitCenter of Calcium and Bone Research (COCAB), Faculty of Science, Mahidol University, Bangkok, Thailand.
Jirawan ThongbunchooCenter of Calcium and Bone Research (COCAB), Faculty of Science, Mahidol University, Bangkok, Thailand.
Narattaphol CharoenphandhuCenter of Calcium and Bone Research (COCAB), Faculty of Science, Mahidol University, Bangkok, Thailand.ORCID 0000-0002-2189-6542
Mahidol University · TH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the potential contributing factors for iron overload-induced osteoporosis is the iron toxicity on bone forming cells, osteoblasts. In this study, the comparative effects of Fe3+ and Fe2+ on osteoblast differentiation and mineralization were studied in UMR-106 osteoblast cells by using ferric ammonium citrate and ferrous ammonium sulfate as Fe3+ and Fe2+ donors, respectively. Effects of 1,25 dihydroxyvitamin D3 [1,25(OH)2D3] and iron chelator deferiprone on iron uptake ability of osteoblasts were examined, and the potential protective ability of 1,25(OH)2D3, deferiprone and extracellular calcium treatment in osteoblast cell survival under iron overload was also elucidated. The differential effects of Fe3+ and Fe2+ on reactive oxygen species (ROS) production in osteoblasts were also compared. Our results showed that both iron species suppressed alkaline phosphatase gene expression and mineralization with the stronger effects from Fe3+ than Fe2+. 1,25(OH)2D3 significantly increased the intracellular iron but minimally affected osteoblast cell survival under iron overload. Deferiprone markedly decreased intracellular iron in osteoblasts, but it could not recover iron-induced osteoblast cell death. Interestingly, extracellular calcium was able to rescue osteoblasts from iron-induced osteoblast cell death. Additionally, both iron species could induce ROS production and G0/G1 cell cycle arrest in osteoblasts with the stronger effects from Fe3+. In conclusions, Fe3+ and Fe2+ differentially compromised the osteoblast functions and viability, which can be alleviated by an increase in extracellular ionized calcium, but not 1,25(OH)2D3 or iron chelator deferiprone. This study has provided the invaluable information for therapeutic design targeting specific iron specie(s) in iron overload-induced osteoporosis. Moreover, an increase in extracellular calcium could be beneficial for this group of patients.

Indexed as

AnimalsBiomarkersCalcification, PhysiologicCalcitriolCalciumCell Cycle CheckpointsCell DeathCell DifferentiationCell LineCell SurvivalDeferiproneExtracellular SpaceIronIron OverloadOsteoblastsRatsBiomarkersCalcitriolCalciumDeferiproneIronReactive Oxygen Species

Identifiers

PMID32470038
PMCPMC7259719
OpenAlexW3029377582

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.